It has also been shown that hypermethylated NPY circulating tumor DNA (meth-ctDNA) may be useful as a biomarker of CRC metastasis and progression and a potential indicator for last-line treatment with regorafenib in metastatic CRC patients [6,10,15,20,21,22,23]. Here, NPY is linked to neoplasm.